Eli Lilly and Company / Kumquat Biosciences, Inc.

Solid Tumors (Small Molecule Immuno-Oncology)

600K US cases/yr · $40.0B Global checkpoint inhibitor + small-molecule IO market 2021 · $70M Upfront payment ($40M cash + $30M equity)

Disease Overview

The Lilly-Kumquat collaboration targets solid tumor immuno-oncology indications using small-molecule modalities designed to stimulate tumor-specific immune responses. The U.S. solid tumor population spans approximately 1.9 million new cancer cases annually, with the immuno-oncology-eligible subset (NSCLC, melanoma, RCC, HCC, urothelial, MSI-H tumors) representing roughly 600,000-800,000 new patients per year. Strategic anchors include non-small cell lung cancer (~236,000 new U.S. cases) and melanoma (~100,000 new U.S. cases) where checkpoint inhibitors have transformed standard of care. Kumquat's small-molecule approach differentiates from the dominant antibody/biologic immuno-oncology paradigm — oral delivery enables better PK control, CNS penetration, intermittent dosing, and combination flexibility relative to anti-PD-1/PD-L1 mAbs. Kumquat was founded by Tony Tontonoz and is backed by Foresite Capital and Lightspeed; Lilly's $70M upfront ($40M cash + $30M equity) and $2B+ biobucks structure positions Kumquat as Lilly's strategic small-molecule immuno-oncology platform partner. WAC pricing for novel checkpoint-class oncology agents ranges $15K-25K per month, with combination regimens often exceeding $30K per month at list.

Competitive Landscape

The small-molecule immuno-oncology landscape is among the most contested adjacencies to the anti-PD-(L)1 antibody backbone. Approved checkpoint backbones include pembrolizumab (Keytruda, Merck, $20B+ revenue), nivolumab (Opdivo, BMS), atezolizumab (Tecentriq, Roche), durvalumab (Imfinzi, AstraZeneca), and cemiplimab (Libtayo, Regeneron/Sanofi). Small-molecule IO competitors include STING agonists (E7766 Eisai, ADU-S100 Aduro/Chinook), TLR7/8 agonists (selgantolimod Gilead, vesatolimod), AhR antagonists (BAY-2416964 Bayer), CD73 small molecules (AB680 Arcus, oleclumab AstraZeneca), A2A receptor antagonists (etrumadenant Arcus, ciforadenant Corvus), and IDO/TDO inhibitors (epacadostat Incyte, navoximod Genentech, indoximod NewLink/Lumos). HPK1 inhibitors are an emerging class led by Genentech, BeiGene, and academic spinouts. Kumquat's small-molecule platform sits in this discovery-stage space; Lilly's strategic logic is to build optionality alongside its tislelizumab partnership with Novartis (since terminated) and Verzenio-anchored solid tumor portfolio. Other big pharma small-molecule IO platform deals include Bristol Myers/Repare ($50M+ upfront 2020) and Roche/Adagene.